Carregant...

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma

Pembrolizumab is an effective therapy in patients with metastatic melanoma. However, not all patients derive benefit. It is postulated that an increase in regulatory T cells in melanoma patients can impair the response to immunotherapies. Continuous low dose temozolomide has shown to cause immunomod...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Melanoma Res
Autors principals: Swami, Umang, Monga, Varun, Freesmeier, Michele, Zhang, Weizhou, Bossler, Aaron D., Zakharia, Yousef, Milhem, Mohammed
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717692/
https://ncbi.nlm.nih.gov/pubmed/30829928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0000000000000592
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!